58 completed, 4 recruiting, 3 terminated, 3 unknown. 26 Phase 2, 18 Phase 3, 8 Phase 1, 7 Not applicable, 7 Phase 4.
Follow Allergic Rhinoconjunctivitis: new trials by email Literature Review of Allergic Rhinoconjunctivitis trials Research Report on Allergic Rhinoconjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure Standardized Allergen Extract, Timothy Grass (Phleum pratense) - Allergic Rhinoconjunctivitis | Recruiting | Dr. Anne Ellis | 12 | 2026-09-01 | 2026-10-01 | |
| Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063. EP-088_MM09, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 3 | Recruiting | Inmunotek S.L. | 250 | 2026-04-15 | 2026-10-29 |
| Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063. EP-088_MM09, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 3 | Recruiting | Inmunotek S.L. | 250 | 2026-02-24 | 2026-10-29 |
| A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 HDM SLIT-tablet (12 SQ-HDM), Placebo - Allergic Rhinoconjunctivitis, Allergic Rhinitis | Phase 3 | Completed | ALK-Abelló A/S | 327 | 2025-09-01 | 2026-10-05 |
| Study of BLU-808 in Allergic Rhinoconjunctivitis BLU-808, Placebo - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Blueprint Medicines Corporation | 21 | 2025-04-14 | 2026-09-03 |
| Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study NovoHelisen Depot - Allergic Rhinoconjunctivitis | Phase 4 | Recruiting | Wroclaw Medical University | 67 | 2024-11-02 | 2025-01-28 |
| Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. Specific immunotherapy (SIT) treatment, Dietary Supplement: ABB C1, Mini-tablets with pork extract - Rhinitis, Allergic Rhinoconjunctivitis | Phase 4 | Completed | Gala Servicios Clinicos S.L. | 60 | 2024-05-29 | 2025-08-29 |
| Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract 3,000 MM09, 9,000 MM09, Placebo sublingual - Allergic Rhinitis, Allergic Asthma | Phase 2 / Phase 3 | Not yet recruiting | Inmunotek S.L. | 90 | 2023-11-01 | 2023-10-23 |
| Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma STALORAL® Birch 300 IR - Allergic Rhinoconjunctivitis, Birch Pollen Allergy | Phase 3 | Completed | Stallergenes Greer | 553 | 2023-09-20 | 2025-11-26 |
| Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL) - House Dust Mite Allergy, Perennial Allergic Rhinitis | Phase 3 | Unknown | Inmunotek S.L. | 400 | 2022-12-01 | 2022-11-18 |
| Effect of holoBLG on Cat Allergic Patients holoBLG - Allergy to Cats, Allergic Rhinoconjunctivitis | Not applicable | Completed | Allergy Therapeutics | 42 | 2021-10-04 | 2023-12-18 |
| Andosan in Allergic and Asthma Patients Andosan, Placebo - Allergic Asthma, Allergic Rhinoconjunctivitis | Not applicable | Completed | University Hospital, Akershus | 34 | 2021-08-31 | 2024-06-18 |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction Dupixent®, Grazax®, Dupixent® Placebo - Allergic Rhinoconjunctivitis, Grass Pollen Allergy | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 199 | 2020-11-05 | 2026-04-27 |
| Adolescent Mite Allergy Safety Evaluation HDM SLIT-tablet - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 3 | Completed | ALK-Abelló A/S | 253 | 2020-09-23 | 2023-07-03 |
| Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray. nasal spray - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Not applicable | Completed | Marinomed Biotech AG | 42 | 2020-08-04 | 2021-02-21 |
| Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis nasal spray, no treatment - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Not applicable | Completed | Marinomed Biotech AG | 42 | 2020-08-04 | 2021-02-21 |
| Probiotic Chewables in Allergic Rhinoconjunctivitis Patients Probiotic chewables, Placebo chewables - Allergic Rhinoconjunctivitis | Not applicable | Completed | University Hospital, Antwerp | 64 | 2020-08-01 | 2022-04-15 |
| A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber Sublingual allergy immunological tablet, Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Terminated | ALK-Abelló A/S | 80 | 2019-11-04 | 2022-06-30 |
| Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis Norketotifen, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | Emergo Therapeutics, Inc. | 36 | 2019-04-01 | 2020-08-21 |
Showing 20 of 69. Sign in to see all of them.
Rhinitis, Allergic (23) · Hypersensitivity (15) · Rhinitis, Allergic, Seasonal (6) · Conjunctivitis, Allergic (5) · Dust Mite Allergy (3) · Rhinitis (3) · Rhinitis, Allergic, Perennial (3) · Chronic Urticaria (1) · Erythema (1) · Nasal Obstruction (1) · Pruritus (1) · Rhinorrhea (1) · Sneezing (1) · Urticaria (1)
Immune System Diseases (37) · Nose Diseases (28) · Otorhinolaryngologic Diseases (28) · Respiratory Tract Diseases (28) · Hypersensitivity, Immediate (26) · Respiratory Hypersensitivity (26) · Rhinitis (25) · Hypersensitivity (22) · Conjunctival Diseases (5) · Conjunctivitis (5) · Eye Diseases (5) · Infections (3) · Respiratory Tract Infections (3) · Rhinitis, Allergic (3) · Airway Obstruction (1)
Grazax (4) · Immunotherapy (3) · Tobacco Use Cessation Devices (2) · grass pollen extract, alum-adsorbed (2) · AndoSan (1) · Carrier State (1) · Cholecalciferol (1) · Pork Meat (1) · Standard of Care (1) · Sublingual Immunotherapy (1) · Sugars (1) · Therapeutics (1) · Thermography (1) · Transdermal Patch (1) · Transfer Factor (1)
ALK-Abelló A/S (11) · HAL Allergy (7) · Roxall Medicina España S.A (6) · Inmunotek S.L. (5) · Allergopharma GmbH & Co. KG (4) · Artu Biologicals (3) · Immunomic Therapeutics, Inc. (2) · Laboratorios Leti, S.L. (2) · Marinomed Biotech AG (2) · ORA, Inc. (2) · Aarhus University Hospital (1) · Allergy Therapeutics (1) · Bitop AG (1) · Blueprint Medicines Corporation (1) · Charite University, Berlin, Germany (1)
Germany (20) · Spain (16) · United States (7) · Austria (6) · Canada (6) · Poland (6) · Czechia (4) · Netherlands (4) · Slovakia (4) · Belgium (3) · Bulgaria (3) · France (3) · Hungary (3) · Lithuania (3) · Portugal (3)
Anne K Ellis, MD (2) · David Fitz-Patrick, MD (2) · Eva Prieschl-Grassauer, PhD (2) · Henry J. Crampton, MD (2) · Paul Gomes, MS (2) · Peter Couroux, MD (2) · Agnieszka M Chuda, MSc (1) · Albert Roger, MD (1) · Alicia Alonso, Dra. (1) · Ana Isabel Tabar Purroy, MD. PhD (1) · Ana Isabel Tabar Purroy, MD; PhD (1) · Andreas Horn, MD (1) · Angel Ferrer, Dr (1)
PMID 22594491, PMID 22939758, PMID 23621350, PMID 24290282, PMID 24679733, PMID 26417901, PMID 28911971, PMID 29432967, PMID 31319883, PMID 32407947, PMID 33905129, PMID 35980665, PMID 37417619, PMID 37488734, PMID 38333020, PMID 38616622, PMID 39534593
2009 (3), 2018 (3), 2008 (1), 2025 (1)